Its active ingredient is recombinant human thrombin rthrombin and the product is indicated as an aid to hemostasis whenever control of bleeding by standard surgical techniques such as suture, ligature. Zymogenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. Recombinant factors for hemostasis unl digital commons. Zymogenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. Food and drug administration today has approved recothrom, the first clotting solution manufactured using recombinant dna. Zymogenetics sues bristolmyers squibb in patent dispute. Fda asks zymogenetics to revise new products press. It moved 40 research and development jobs to san francisco in 2015, leaving its seattle operations primarily a manufacturing office. Get the inside scoop on jobs, salaries, top office locations, and ceo insights.
The company has been winding down its seattle operations for some time. Zymogenetics claims that recothrom avoids complications associated with kings animalderived product, which is sold with a warning regarding the potential for abnormalities, including severe. Another option for producing an ample amount of rfi is production in transgenic animals. Zymogenetics is a fullyintegrated research and development organization with a broad range of skills. The waiting period expiration satisfies a condition of the tender offer. Find out what works well at zymogenetics from the people who know best. Reviews from zymogenetics employees about zymogenetics culture, salaries, benefits, worklife balance, management, job security, and more.
The remaining 120 manufacturing jobs in seattle will focus on early manufacturing for toxicology and clinical trials, according to the seattle times. Recothrom, the first and only recombinant thrombin, is now available in both 5,000 and 20,000iu vial sizes, said bruce l. Zymogenetics announces fda approval of recothromtm. Bristol myers squibb is an equal oppurtunity employer.
The companys filing status is listed as currentactive and its file number is 1012676. Spray applicator kit zymogenetics sterile 1 ea zymogenetics. Seattle, wa, usa january 17, 2008 zymogenetics, inc. Zymogenetics, llc is a north carolina limitedliability company filed on november 16, 2007. Zymogenetics, inc was one of the oldest biotechnology pharmaceutical companies in the usa, based in seattle, washington. Zymogenetics in seattle, wa get driving directions to 1201 eastlake ave e seattle, wa 98102. Zymogenetics bruce carter on recothrom by joseph tartakoff on august 6, 2008 at 11. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, bciq provides. Zymogenetics will continue to build the market for its approved product, recothrom thrombin, topical recombinant, while pursuing the research, development and commercialization of novel biologic therapeutics. College lab in bothell, wa foursquare uses cookies to provide you with an optimal experience, to personalize ads that you may see, and to help advertisers. Zgen today announced that the united states food and drug administration fda has approved recothromtm fda approves zymogenetics recothrom tm thrombin, topical. Bristolmyers squibb is a global biopharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Zymogenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. Safety and low immunogenicity observed in patients undergoing skin grafting for burns seattlebusiness wirezymogenetics, inc. The cell line used to manufacture recothrom has been tested and shown to be. The zymogenetics headquarters lake union steam plant building, a concrete frame structure 90 feet wide and 316 feet long, was completed in 1921. Qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national. Recothrom is a surgical hemostat that is applied topically to stop bleeding during surgery. Recothrom thrombin topical recombinant, manufactured using a recombinant technology, provides hospitals and their healthcare providers an innovative. Zymogenetics licenses recombinant factor xiii to novo. The move is part of a broader realignment of research and manufacturing facilities by the biotech companys. The seattle companys product is a genetically engineered form of thrombin.
Recothrom is zymogenetics first product and the company said in its latest annual report filed with the sec that it was at least several years away from profitability. I agree to receive occasional updates and announcements about forbes products and services. The april 2012 digital edition of pharmacy practice news by. Recothrom thrombin, topical recombinant prescription rx. Peginterferon lambda, being studied in collaboration with bristolmyers squibb for treatment of hepatitis c virus infection, and il21, being. Bristol myers squibb industry leadership in biopharma. Food and drug administration says zymogenetics omitted important facts when announcing the launch of its first commercial product, recothrom, and it asked the company to revise the press. Bristolmyers squibb relocating 40 seattle scientists to. Recothrom helps stop small blood vessels from bleeding after surgery. Recothrom, thrombin topical recombinant, is a topical thrombin indicated to aid. Zymogenetics has said that most of recothroms sales will take place during. The zymogenetics board of directors has directed shareholders to accept the offer and tender their shares to bristolmyers squibb. Bristolmyers squibb to buy zymogenetics the new york times.
Zymogenetics inc company profile and news bloomberg. See who you know at zymogenetics, leverage your professional network, and get hired. Id like to receive the forbes daily dozen newsletter to get the. Zymogenetics will become independent of novo nordisk.
The company was involved in the development of therapeutic proteins. Bristolmyers squibb will retain responsibility for the manufacturing of recothrom and will be the medicine companys exclusive supplier of recothrom during the term of the agreement. Recothrom, thrombin topical recombinant package insert fda. Fda approves zymogenetics recothromtm thrombin, topical. Zymogenetics licenses antibody, cuts staff december 14. Bms acquires zymogenetics bristolmyers squibbs hepatitis c, oncology and immunoscience portfolios will be strengthened with new purchase bristolmyers squibb bms is to strengthen its portfolio in. Zymogenetics, located in the old seattle city light steam plant on along lake union. Spray applicator kit zymogenetics sterile 1 ea zymogenetics 28400070017 spray applicator kit zymogenetics sterile 1 ea zymogenetics 28400070017. Located on lake union, the address of the zymogenetics headquarters was 1201 eastlake avenue east it was closed in 2019 after its acquisition by bristol myers squibb 3.
Bristolmyers squibb to acquire zymogenetics bms newsroom. Recothrom thrombin, topical recombinant zymogenetics. As ceo of zymogenetics transformed a small private discovery company into a public company nasdaqwhich launched recothrom on the market and put a number of drugs into clinical trials. The medicines company and bristolmyers squibb agree to. The company developed and is marketing recothrom thrombin, topical recombinant in the united states. Cms releases updates and software to macs as well as quarterly and. Both companies have approved the deal and the board of zymogenetics is recommending that shareholders support the bid. The company will discontinue ongoing research activities in oncology and focus future research efforts in immunology, its core strength. Food and drug administration says zymogenetics omitted important facts when announcing the launch of its first commercial product, recothrom, and it asked the company to revise the press release. Zymogenetics has two product candidates in phase 2 clinical development.
2 1118 1412 1397 1425 741 1583 1345 322 259 423 897 1056 128 239 387 862 592 147 866 852 762 1052 866 777 1388 1239 1282 611 496 591 1201 743 1187